SCHEMBL798763

SCHEMBL798763

CC(COc1ccccc1)(NC=O)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.42
ALPL P05186 1/20 0.41
ALPI P09923 1/20 0.41
ALPG P10696 1/20 0.41
SSTR4 P31391 1/20 0.41
MTNR1A P48039 4/20 0.41
MTNR1B P49286 4/20 0.41
ALOX15 P16050 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 2/20 0.40
CASP3 P42574 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
PPARG P37231 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5309684 0.78 ALPL (0.44) PPARAALPLALPIALPGSSTR4
SCHEMBL17506734 0.76 CYP3A4 (0.47) PPARAALOX15PPARGPOLBHPGD
SCHEMBL3465226 0.75 PPARA (0.47) PPARAALPLALPIALPGSSTR4
SCHEMBL5724626 0.74 PPARA (0.58) PPARASSTR4ALOX15PPARG
SCHEMBL7805112 0.73 PPARA (0.49) PPARAALPLALPIALPGSSTR4
SCHEMBL14975398 0.72 NPC1 (0.46) PPARARAB9ANPC1CASP3SENP7
SCHEMBL2517194 0.71 ALDH1A1 (0.60) PPARAALPLALPIALPGSSTR4
SCHEMBL97622 0.71 KCNA3 (0.41) PPARAALPLALPIALPGSSTR4
SCHEMBL5266201 0.70 PPARA (0.48) PPARAALPLALPIALPGSSTR4
SCHEMBL5367643 0.70 SSTR4 (0.51) PPARAALPLALPIALPGSSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12011496-B2 Topical macqui berry formulation Tracie Martyn International, Inc. (US) 2024-06-18 US disclosed
US-10993897-B2 Topical macqui berry formula Tracie Martyn International, Inc. (US) 2021-05-04 US disclosed
US-20190151227-A1 TOPICAL MACQUI BERRY FORMULA TRACIE MARTYN INT INC (US) 2019-05-23 US disclosed
US-20170027853-A1 TOPICAL MACQUI BERRY FORMULATION TRACIE MARTYN INTERNATIONAL, LLC 2017-02-02 US disclosed
US-9463153-B2 Topical macqui berry formulation Trade Martyn International, LLC (US) 2016-10-11 US disclosed
US-20150150770-A1 METHODS OF TREATING SKIN TRACIE MARTYN INTERNATIONAL INC (US) 2015-06-04 US disclosed
US-9040553-B2 Phenoxyisobutyric acid compounds and method of synthesis Cell Viable Corporation (US) 2015-05-26 US disclosed
US-20140377338-A1 TOPICAL MACQUI BERRY FORMULATION TRACIE MARTYN INTERNATIONAL, LLC 2014-12-25 US disclosed
US-20140371316-A1 DERIVATIVES OF PHENOXYISOBUTYRIC ACID FABRICANT JILL S (US) 2014-12-18 US disclosed
US-20140350045-A1 PHENOXYISOBUTYRIC ACID COMPOUNDS AND METHOD OF SYNTHESIS LALEZARI IRAJ (US) 2014-11-27 US disclosed
US-20020013256-A1 Novel inhibitors of formation of advanced glycation endproducts (AGES) PROSCIENCE CORPORATION, INCORPORATED IN THE STATE OF NEW YORK 2002-01-31 US disclosed
US-6337350-B1 CROSSLINKING INHIBITION OF PROTEINS CITY OF HOPE 2002-01-08 US disclosed
US-6337350-B1 CROSSLINKING INHIBITION OF PROTEINS CITY OF HOPE 2002-01-08 US disclosed
US-20020002203-A1 Novel breakers of advanced glycation endproducts CITY OF HOPE 2002-01-03 US disclosed
EP-1165064-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) City of Hope (US) 2002-01-02 EP disclosed
EP-1165064-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) City of Hope (US) 2002-01-02 EP disclosed
WO-2001076584-A2 USE OF BREAKERS OF ADVANCED GLYCATION ENDPRODUCTS FOR TREATING DELETERIOUS EFFECTS OF AGING AND DEBILITATING DISEASES CITY OF HOPE (US) 2001-10-18 WO disclosed
WO-2000059875-A3 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) HOPE CITY (US) 2001-03-29 WO disclosed
WO-2000059875-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) CITY OF HOPE (US) 2000-10-12 WO disclosed
WO-2000059875-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) CITY OF HOPE (US) 2000-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002203-A1 Novel breakers of advanced glycation endproducts AGER, SSB, MRPS18B PPARA 1868/4885ALPL 4660/4885ALPI 4163/4885
US-20140350045-A1 PHENOXYISOBUTYRIC ACID COMPOUNDS AND METHOD OF SYNTHESIS AGER, BPGM, PDXK PPARA 262/4885ALPL 1930/4885ALPI 719/4885
US-20150150770-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT PPARA 192/4885ALPL 1692/4885ALPI 2530/4885
US-20140371316-A1 DERIVATIVES OF PHENOXYISOBUTYRIC ACID AGER, BPGM, FOSB PPARA 287/4885ALPL 3196/4885ALPI 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.